IKS-03

N/A

Report date: 2024/01/25 16:19:04

Base Information

Drug NameIKS-03
Drug Alias NameIKS-03NI-2201LCB 73IKS 03
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-CD19
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma, Mantle-CellLymphoma, FollicularLymphoma, Large B-Cell, Diffuse +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesItaly +[6] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesLegochem Biosciences IncNovimmune Sa
China Registration ClassN/A

Develop Information

Active CompaniesIksuda Therapeutics
Inactive CompaniesN/A
Active IndicationsLymphoma, Mantle-CellLymphoma, FollicularLymphoma, Large B-Cell, Diffuse +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A